Novartis Korea to register Certican, an immuno-suppressant.

Novartis Korea took an KFDA approval of Certican (everolimus), an immuno suppressing drug on April 24

Certican is a proliferation signal inhibitor for the prophylaxis of organ rejection in heart and kidney transplant patients who are in moderate and severe immunological risk, which can be used in combination with cyclosporine in micro emulsion forms and corticoids.

The clinical study rep...